trastuzumab

Ligand id: 5082

Name: trastuzumab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: trastuzumab

Classification
Compound class Antibody
Approved drug? Yes (FDA (1998), EMA (2000))
WHO Essential Medicine WHO Model List of Essential Medicines (21st List, 2019). Access PDF version.
International Nonproprietary Names
INN number INN
7637 trastuzumab
Synonyms
D5v8 | Herceptin® | R-597
Comments
Trastuzumab is a humanized IgG1κ monoclonal antibody targeting HER2.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

Biosimilars:
NameTrade nameCompanyClinical PhaseIndications
trastuzumab-dkst; MYL-1401OHertraz; Canmab; OgivriMylan and Biocon Approved in India, FDA 2017, EMA 2018 (Ogivri)Breast cancer
trastuzumab-pkrb; CT-P6Herzuma; CredimaCelltrionApproved in S Korea, EMA & FDA 2018Breast cancer
trastuzumab-dttb; SB3OntruzantSamsung BioepisApproved (EMA 2017, FDA 2019)All approved indications of the reference product
trastuzumab-beta; trastuzumab-anns; ABP-980 [3]KanjintiAmgen/AllerganApproved (EMA 2018, FDA 2019)All approved indications of the reference product
HLX02 Shanghai Henlius BiotechPh 3 (NCT03084237)Breast cancer
trastuzumab-qyyp; PF-05280014TrazimeraPfizerApproved (FDA 2019; see REFLECTIONS B327-02 trial NCT01989676)All approved indications of the reference product
Database Links
Specialist databases
IMGT/mAb-DB 97
Other databases
GtoPdb PubChem SID 178101775
PubChem SID 178101775
Search PubMed clinical trials trastuzumab
Search PubMed titles trastuzumab
Search PubMed titles/abstracts trastuzumab
Wikipedia Trastuzumab